0001209191-22-013160.txt : 20220225 0001209191-22-013160.hdr.sgml : 20220225 20220225161819 ACCESSION NUMBER: 0001209191-22-013160 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220223 FILED AS OF DATE: 20220225 DATE AS OF CHANGE: 20220225 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Alam Kamran CENTRAL INDEX KEY: 0001793412 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 22680262 MAIL ADDRESS: STREET 1: 350 FIFTH AVENUE, SUITE 7530 CITY: NEW YORK STATE: NY ZIP: 10118 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-23 0 0001806310 Taysha Gene Therapies, Inc. TSHA 0001793412 Alam Kamran C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, STE 1430 DALLAS TX 75247 0 1 0 0 Chief Financial Officer Employee Stock Option (right to buy) 5.96 2022-02-23 4 A 0 80000 0.00 A 2032-02-23 Common Stock 80000 80000 D 25% of the total number of shares underlying the option shall vest and become exercisable on February 23, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Kamran Alam 2022-02-25